Double-tract reconstruction is superior in controlling reflux esophagitis and enhancing quality of life after proximal gastrectomy: Results from a prospective randomized controlled clinical trial in China

DOI: https://doi.org/10.21203/rs.3.rs-1960657/v1

Abstract

Background

Proximal gastrectomy (PG) is an alternative function preserving surgery. The aim of this study was to prospectively compare double-tract reconstruction (DTR) and esophagogastrostomy (EG) after PG regarding the incidence of reflux esophagitis, quality of life (QOL), nutritional status and surgical safety.

Method

This study was a prospective, randomized controlled trial conducted in a single institute. Patients eligible for PG were enrolled and randomly assigned to the EG group and DTR group. The characteristic of patients, parameters of surgical safety, the incidence of reflux esophagitis, nutrition status and the QOL were compared between the EG and the DTR group. Univariate analysis and multivariate analysis were performed to determine the significant factor affecting the incidence of reflux esophagitis after PG.

Results

73 patients eligible for PG were enrolled in the study and randomly assigned to the EG group (37 patients) and DTR group (36 patients). The incidence of reflux esophagitis after PG was significantly lower in the DTR group than that of the EG group (8.3% vs. 32.4%, Pā€‰=ā€‰0.019). In multivariate analysis, reconstruction method was the only significant factor affecting the incidence of reflux esophagitis. The DTR group demonstrated a more favorable QOL than the EG group after PG in the global health status, emotional functioning and symptoms such as fatigue, nausea and vomiting, pain, insomnia, appetite loss, dysphagia, reflux, eating restrictions, anxiety, dry mouth and taste change were more severe in the EG group patients. Nutritional status was balanced within the EG group and the DTR group after PG including BMI, levels of hemoglobin, serum albumin and serum total protein. The operation time was longer in the DTR group than in the EG group (191min vs. 221min, Pā€‰=ā€‰0.001) while surgical safety was similar in the two groups regarding blood loss volume, postoperative complications and hospital stays.

Conclusion

Our research demonstrated that DTR was superior to EG after PG in terms of the incidence of reflux esophagitis and provided a more satisfied QOL without increasing surgical complications or sacrificing nutritional status, thus making DTR a better reconstruction method after PG.

Trial registration

ClinicalTrials.gov, NCT 03613142, registered on August 2, 2018.

Mini-abstract

Double-tract reconstruction is superior to esophagogastrostomy after proximal gastrectomy regarding the incidence of reflux esophagitis and provides a more satisfactory quality of life.

Introduction

Gastric cancer (GC) is estimated to be the fifth most commonly diagnosed malignant tumor and ranks fourth in mortality worldwide(1). China has the most gastric cancer patients worldwide and contributed 45% of new cases (478,000) in 2020(2, 3). Although the rate of GC has decreased in the past three decades, the number of new cases and deaths from GC are estimated to increase(4). Moreover, the incidence of proximal gastric cancer, including gastroesophageal junction (EGJ) cancer, has been rising over the past few decades(5, 6).

The traditional surgical approach for gastric cancer located in the upper third of the stomach, including the EGJ, is total gastrectomy(7, 8). However, total gastrectomy may cause nutritional disadvantages, especially with respect to vitamin B12 and iron, due to the lack of intrinsic factor secreted by parietal cells in the distal stomach, which results in megaloblastic anemia. Moreover, the loss of storage capacity of the stomach and the function of the pylorus may lead to prolonged food intake restriction(9, 10). Proximal gastrectomy (PG) is considered a gastric-preserving surgery and a curative method for early gastric cancer that is located in the upper one-third of the stomach; such treatment with PG is recommended by the Japanese guideline for gastric cancer(7, 11). A large retrospective study demonstrated that for EGJ adenocarcinoma less than 4 cm, complete lymphadenectomy of the distal portion of the stomach offers marginal survival benefits so that PG can be considered in these patients(12). Moreover, for advanced proximal GC patients with cT2-3 staging, since the incidence of No. 4d, 5, 6 and 12a lymph node metastasis is extremely low, proximal gastrectomy would also be a choice for these patients(13, 14). Since the distal part of the stomach and pylorus is preserved, PG not only causes an improved nutritional status that includes the hemoglobin level, serum total protein level, and serum albumin level but also yields a better quality of life (QOL) in terms of more food intake and less body weight loss(10, 15, 16).

The common reconstruction method for PG includes esophagogastrostomy (EG), double-tract reconstruction (DTR), and jejunal interposition (JI), with the former two procedures being more commonly adopted. Reflex symptoms (occurring as the result of preservation of the stomach and lack of the cardia) such as sour regurgitation, heartburn, chest pain, and anorexia, are associated with reflux esophagitis, which is most considered when choosing a construction method after PG(17, 18). Since the majority of PG patients are early gastric cancer patients or patients with relatively small tumors, the QOL after surgery is another crucial consideration along with the prognosis(19, 20). In another previous retrospective study, DTR demonstrated better prevention of reflux esophagitis and improved quality of life(21). However, there is no prospective trial comparing EG and DTR after PG. Therefore, the main purpose of this study was to compare the difference between DTR and EG after radical proximal gastrectomy, regarding the incidence of postoperative reflux esophagitis, the postoperative QOL, surgical safety, and the postoperative nutritional status.

Methods

Study design

This trial is a prospective, randomized controlled study conducted in a single large cancer center, Peking University Cancer Hospital Gastrointestinal Cancer Center. Patients eligible for radical proximal gastrectomy from January 2019 to May 2021 were enrolled and randomly assigned to the DTR group or the EG group. The study conformed to the Declaration of Helsinki and was approved by the Ethics Committee of Peking University Cancer Hospital (No. 2018KT97). This trial was registered on the ClinicalTrials website before patient recruitment (NCT 03613142).

Patients

Patients aged 18 to 80 years, with an Eastern Cooperative Oncology Group performance status score of 0 or 1, histologically confirmed adenocarcinoma, without metastasis, located in the upper one-third stomach and classified at clinical stage T1N0M0 (8th edition of the Union for International Cancer Control/American Joint Committee on Cancer TNM staging) or those with gastroesophageal junction cancer (Siewert type II or III) with a diameter less than 4 cm, who were eligible for R0 radical PG were involved in the study. Patients with distant metastatic lesions, with synchronous gastric cancer or malignancies in other organs, with a previous gastric surgery history (not including endoscopic resection) or with other conditions not suitable for surgery were excluded from the study. All patients volunteered to participate and signed informed consent forms before enrollment.

Surgery

All patients first underwent laparoscopic exploration to exclude peritoneal metastasis. Then, patients without metastasis underwent radical proximal gastrectomy with standard lymphadenectomy according to the Japanese gastric cancer treatment guidelines, which required resection of the upper half of the stomach and the abdominal segment of the esophagus with lymph node dissection of No. 1, 2, 3a, 4sa, 4sb, 7, 8a, 9, and 11p(7). Finally, EG or DTR was performed. DTR procedure (shown in supplementary files.): After transection of the esophagus, the 25 mm anvil of the circular stapler was inserted directly into the esophagus stump or by the transoral anvil delivery system (EEA OrVil™). The jejunum was transected 20 to 25 cm below the Treitz ligament. The distal jejunum was anastomosed with the esophagus by end-to-side anastomosis, and the jejunal stump was closed with a 60 mm linear stapler. The gastrojejunostomy was performed 15 cm below the esophagojejunostomy with side-to-side anastomosis by a 60 mm linear stapler, and the jejunojejunostomy was performed 15 cm below the gastrojejunostomy with side-to-side anastomosis by a 60 mm linear stapler. The common entry holes of the gastrojejunostomy and the jejunojejunostomy were closed by a linear stapler or manual suture. EG procedure: The placement of the anvil was the same as mentioned before; then, the esophagus was directly anastomosed with the remnant stomach by a 25 mm circular stapler with the anastomosis located in the anterior wall of the greater curvature of the gastric remnant.

Follow-up

Gastroscopy was performed approximately twelve months after the operation to evaluate reflux esophagitis according to the Los Angeles Classification of Gastroesophageal Reflux Disease. A nutritional evaluation was performed every three months after the operation, including the measurement of body weight and examination of the level of hemoglobin, albumin, and total protein in the blood test. QOL was assessed by the EORTC QLQ-C30 (version 3.0) and STO22 questionnaires approximately twelve months after surgery.

Endpoint

The primary endpoint of the study was the incidence of reflux esophagitis after surgery, which was diagnosed and evaluated by gastroscopy and was classified by the Los Angeles classification (grades A to D). Secondary endpoints included postoperative QOL, postoperative nutritional status, surgical safety, and postoperative recovery.

Statistical analysis

The expected incidence of reflux esophagitis after EG and DTR was about 31% and 8%, respectively(21). On the basis of that, a type I error of 5% and a power of 80%, 33 patients were needed in each group and assuming a dropout rate of 10%, 36 patients were needed in each group (total 72 patients).

The statistical analysis was performed with SPSS software (version 25.00.1; International Business Machines Corporation, Armonk, NY). For continuous variables, a test of normality was first performed. Normally distributed variables were presented as the mean ± standard deviation (SD), and differences between groups were analyzed using Student’s t test. Nonnormally distributed variables were presented as the median and the interquartile range, and a nonparametric test was applied to calculate the difference between groups. The chi-squared test and Fisher’s exact test (when appropriate) were adopted to compare categorical variables. Logistic regression was applied in multivariate analysis to determine the independent factors affecting reflux esophagitis. All values were two-tailed, and P values < 0.05 were regarded as statistically significant differences.

Results

Patient characteristics

There were 98 patients initially screened for the study from January 2019 to May 2021, among whom 73 patients met the inclusion criteria and were enrolled in the trial, including 37 patients in the EG group and 36 in the DTR group. After one year of follow-up, 3 patients in the DTR group and 4 patients in the EG group were lost to follow-up. The baseline characteristics of the patients are shown in Table 1. No difference was observed regarding the patient demographics, including sex, age and BMI, and the tumor characteristics, including location, size, staging, and other pathology results, such as differentiation types, Lauren’s classification types, LVI and PNI, were similar between the two groups.

Table 1

Clinical and pathological characteristics of the patients

Clinicopathological characteristics

EG (n = 37)

DTR (n = 36)

P value

Sex

   

0.515

Male

33 (89.2%)

30 (83.3%)

 

Female

4 (10.8%)

6 (16.7%)

 

Age (years)

64.6 ± 10.0

64.8 ± 9.0

0.865

BMI (kg/m2)

25.1 ± 3.5

24.9 ± 3.0

0.762

NACT

   

0.530

No

30 (81.1%)

27 (75.0%)

 

Yes

7 (18.9%)

9 (25.0%)

 

ACT

   

0.534

No

16 (43.2%)

13 (36.1%)

 

Yes

21 (56.8%)

23 (63.9%)

 

Borrmann type

   

0.681

EGC

14 (37.8%)

16 (44.4%)

 

I

0 (0%)

1 (2.8%)

 

II

7 (18.9%)

6 (16.7%)

 

III

16 (43.2%)

13 (36.1%)

 

Tumor size (cm)

3.1 ± 1.4

2.7 ± 1.1

0.187

pT stage

   

0.428

T1a

7 (18.9%)

5 (13.9%)

 

T1b

7 (18.9%)

11 (30.6%)

 

T2

7 (18.9%)

3 (8.3%)

 

T3

15 (40.5%)

14 (38.9%)

 

T4a

1 (2.7%)

3 (8.3%)

 

No. of harvested LNs

25.7 ± 8.2

26.4 ± 8.1

0.732

pN stage

   

0.325

N0

18 (48.6%)

25 (69.4%)

 

N1

7 (18.9%)

6 (16.7%)

 

N2

7 (18.9%)

2 (5.6%)

 

N3a

4 (10.8%)

2 (5.6%)

 

N3b

1 (2.7%)

1 (2.8%)

 

pTNM stage

   

0.510

Ia

5 (13.5%)

11 (30.6%)

 

Ib

6 (16.2%)

6 (16.7%)

 

IIa

15 (40.5%)

12 (33.3%)

 

IIb

5 (13.5%)

3 (8.3%)

 

IIIa

3 (8.1%)

1 (2.8%)

 

IIIb

3 (8.1%)

2 (5.6%)

 

IIIc

0 (0.0%)

1 (2.8%)

 

Tumor location

   

0.756

EGJ Siewert II

19 (51.4%)

21 (58.3%)

 

EGJ Siewert III

7 (18.9%)

7 (19.4%)

 

Upper

11 (29.7%)

8 (22.2%)

 

Differentiation

   

0.130

Well

2 (5.4%)

6 (16.7%)

 

Middle

22 (59.5%)

14 (38.9%)

 

Low

13 (35.1%)

16 (44.4%)

 

Lauren’s classification

   

0.513

Intestinal

25 (67.6%)

21 (58.3%)

 

Diffused

3 (8.1%)

6 (16.7%)

 

Mixed

9 (24.3%)

9 (25.0%)

 

LVI

   

0.401

No

19 (51.4%)

22 (61.1%)

 

Yes

18 (48.6%)

14 (38.9%)

 

PNI

   

0.373

No

22 (59.5%)

25 (69.4%)

 

Yes

15 (40.5%)

11 (30.6%)

 

Degree of LN dissection

   

0.200

D1/D1+

14 (37.8%)

19 (52.8%)

 

D2

23 (62.2%)

17 (47.2%)

 

Proximal margin (cm)

2.2 ± 1.2

2.1 ± 1.1

0.605

Distal margin (cm)

5.4 ± 2.0

5.4 ± 2.4

0.933

EG: esophagogastrostomy, DTR: double-tract reconstruction, BMI: body mass index, NACT: neoadjuvant chemotherapy, ACT: adjuvant chemotherapy, EGC: early gastric cancer, EGJ: gastroesophageal junction, LVI: lymphovascular invasion, PNI: peripheral nerve invasion, LN: lymph node


Surgical safety

With respect to surgical safety, there was no significant difference between the EG group and the DTR group, as shown in Table 2. The blood loss volume, postoperative complication rate and length of hospital stay were comparable between the EG and DTR groups. There was no grade III (Clavien–Dindo classification) complication in the EG group, while grade III complications of anastomotic leakage (1/36, 2.78%) and anastomotic bleeding (1/36, 2.78%) occurred in the DTR group. Meanwhile, the DTR group’s average operation time was significantly longer than that of the EG group, 221 minutes and 191 minutes, respectively (P = 0.001). There was no reoperation or death within the two groups 30 days after surgery.

Table 2

Intraoperative and postoperative characteristics of the patients

Perioperative characteristics

EG (n = 37)

DTR (n = 36)

P value

Postoperative hospital stays (day)

11.0 (9.5–11.5)

11.5 (10.0–14.0)

0.058

Blood loss volume (ml)

50 (50–100)

50 (50–100)

0.415

Operation duration (min)

191 (173–219)

221 (200–257)

0.001

Postoperative complications

   

0.736

No

33 (89.2%)

31 (86.1%)

 

Yes

4 (10.8%)

5 (13.9%)

 

Clavien–Dindo classification

     

Grade I

     

Peritoneal effusion

0

1

 

Grade II

     

Anastomotic leakage

0

1

 

Gastrointestinal obstruction

1

1

 

Peritoneal effusion

2

1

 

Pulmonary infection

2

0

 

Anemia

1

0

 

Grade III

     

Anastomotic leakage

0

1

 

Anastomotic bleeding

0

1

 

Postoperative 30-day reoperation

   

> 0.99

No

37

36

 

Yes

0

0

 

Postoperative 30-day death

   

> 0.99

No

37

36

 

Yes

0

0

 

Reflux esophagitis

   

0.019

No

25 (67.6%)

33 (91.7%)

 

Yes

12 (32.4%)

3 (8.3%)

 

Los Angeles classification

     

A

9 (24.3%)

3 (8.3%)

 

B

3 (8.1%)

0 (0.0%)

 
EG: esophagogastrostomy, DTR: double-tract reconstruction

 

Reflux esophagitis

The incidence of reflux esophagitis 12 months after surgery, which was the primary endpoint of the trial, was significantly higher in the EG group than in the DTR group, that was, 32.4% and 8.3%, respectively (P = 0.019). Moreover, reflux esophagitis was more severe in the EG group, in which the rates of grade A and grade B esophagitis were 24.3% and 8.1%, respectively. In contrast, within the DTR group, the incidence of grade A esophagitis was 8.3%, and no grade B esophagitis occurred, which was a significant difference. In univariate analysis, operation duration, blood loss volume and reconstruction method were associated with reflux esophagitis, while in the next step of multivariate analysis, it was demonstrated that only the reconstruction method was a significant factor affecting reflux esophagitis (P = 0.049, Table 3).

Table 3

Univariate analysis and multivariate logistic regression analysis of reflux esophagitis

Univariate analysis

P value

Multivariate analysis

OR (95% CI)

P value

Age

0.865

Reconstruction method

 

0.049

Gender

0.083

DTR

1

 

BMI

0.762

EG

4.416

(1.009–19.324)

 

Tumor location

0.096

     

Proximal margin

0.605

     

Distal margin

0.933

     

Differentiation

0.751

     

Lauren classification

0.964

     

Tumor size

0.187

     

pT stage

0.146

     

pN stage

0.823

     

pTNM stage

0.395

     

Number of harvested LNs

0.732

     

Degree of LND

0.898

     

LVI

0.804

     

PNI

0.691

     

NACT

0.618

     

Adjuvant chemotherapy

0.981

     

Operation duration

0.050

     

Blood loss volume

0.015

     

Postoperative hospital stays

0.480

     

Postoperative complication

0.454

     

Reconstruction method

0.019

     
BMI: body mass index, LN: lymph node, LND: lymph node dissection, LVI: lymphovascular invasion, PNI: peripheral nerve invasion, NACT: neoadjuvant chemotherapy, DTR: double-tract reconstruction, EG: esophagogastrostomy

 

Nutritional status

Nutritional status, including BMI, hemoglobin, serum albumin and serum total protein, demonstrated no significant difference between the EG and the DTR groups when evaluated at 3, 6 and 12 months after surgery (shown in Table 4 and Fig. 1).

Table 4

Postoperative nutritional status of the patients

Nutritional parameters

EG (n = 37)

DTR(n = 36)

P value

BMI (kg/m2)

     

Pre-operation

25.1 ± 3.5

24.9 ± 3.0

0.762

3 months post-operation

21.9 ± 3.4

21.5 ± 2.7

0.603

6 months post-operation

22.0 ± 3.5

21.8 ± 2.8

0.704

12 months post-operation

22.1 ± 3.6

23.1 ± 2.5

0.208

HGB (g/L)

     

Pre-operation

135.9 ± 18.5

131.6 ± 18.0

0.317

3 months post-operation

120.1 ± 16.7

116.5 ± 18.7

0.380

6 months post-operation

125.4 ± 16.4

125.2 ± 17.3

0.946

12 months post-operation

130.3 ± 14.7

130.0 ± 16.7

0.918

ALB (g/L)

     

Pre-operation

45.8 ± 3.9

45.9 ± 3.4

0.905

3 months post-operation

37.9 ± 3.8

37.8 ± 3.7

0.925

6 months post-operation

40.7 ± 4.0

40.5 ± 3.7

0.866

12 months post-operation

41.2 ± 3.9

42.0 ± 3.8

0.395

Total protein (g/L)

     

Pre-operation

70.8 ± 5.2

72,2 ± 5.7

0.285

3 months post-operation

61.1 ± 4.2

60.7 ± 4.6

0.685

6 months post-operation

64.5 ± 4.1

64.4 ± 4.9

0.962

12 months post-operation

64.6 ± 3.9

66.0 ± 4.5

0.156

DTR: double-tract reconstruction, EG: esophagogastrostomy, BMI: body mass index, HGB: hemoglobin, ALB: albumin

 

Quality of life

In general, the DTR group demonstrated a more favorable quality of life than the EG group as assessed by the EORTC QLQ-C30 (version 3.0) and the QLQ-STO22 questionnaire, as shown in Table 5 and Fig. 2A-C. The average global health status (GHS) scores of the DTR group and the EG group were 83.3 and 50.0, respectively, which were significantly different (P < 0.001). Among the functional scales, the DTR group’s emotional functioning (EF) score was significantly superior to that of the EG group, 70.8 and 50.0, respectively (P < 0.001), while other scale scores, including physical functioning (PF), role functioning (RF), cognitive functioning (CF) and social functioning (SF), showed no difference. Regarding the symptoms scales, the EG group patients suffered more from symptoms such as fatigue (FA) (P < 0.001), nausea and vomiting (NV) (P < 0.001), pain (PAIN) (P < 0.001), insomnia (SL) (P < 0.001) and appetite loss (AP) (P < 0.001), while other symptoms, including dyspnea (DY), constipation (CO) and diarrhea (DI), occurred evenly in the two groups. Financial difficulties (FI) were similar within the two groups.

Table 5

The scores from the EORTC QLQ-C30 version 3.0 questionnaire and EORTC QLQ-STO22 questionnaire

Scales

EG, median (IQR)

DTR, median (IQR)

P value

EORTC QLQ-C30

     

Global health status

50.0 (33.3–50.0)

83.3 (66.7–83.3)

< 0.001

Functional scales

     

Physical functioning

80.0 (66.7–83.3)

80.0 (66.7–86.7)

0.220

Role functioning

66.7 (66.7–66.7)

66.7 (66.7–83.3)

0.101

Emotional functioning

50.0 (41.7–62.5)

70.8 (66.7–83.3)

< 0.001

Cognitive functioning

100.0 (66.7–100.0)

100.0 (70.8–100.0)

0.337

Social functioning

66.7 (66.7–66.7)

66.7 (66.7–83.3)

0.087

Symptom scales

     

Fatigue

33.3 (33.3–55.6)

33.3 (2.8–33.3)

< 0.001

Nausea and vomiting

66.7 (50.0-83.3)

16.7 (16.7–16.7)

< 0.001

Pain

33.0 (33.3–50.0)

8.3 (0.0-33.3)

< 0.001

Dyspnea

0.0 (0.0-33.3)

0.0 (0.0–0.0)

0.182

Insomnia

33.3 (0.0–50.0)

0.0 (0.0–0.0)

< 0.001

Appetite loss

33.3 (33.3–66.7)

0.0 (0.0-33.3)

< 0.001

Constipation

0.0 (0.0-33.3)

0.0 (0.0–0.0)

0.097

Diarrhea

0.0 (0.0-33.3)

0.0 (0.0–0.0)

0.086

Financial difficulties

33.3 (0.0-33.3)

33.3 (0.0-33.3)

0.368

EORTC QLQ-STO22

     

Dysphagia

33.3 (22.2–44.4)

22.2 (11.1–22.2)

< 0.001

Pain

41.7 (33.3–66.7)

25.0 (16.7–33.3)

< 0.001

Reflux

88.9 (66.7–100.0)

33.3 (22.2–66.7)

< 0.001

Eating restrictions

41.7 (33.3–66.7)

33.3 (25.0-47.9)

0.001

Anxiety

88.9 (66.7–100.0)

66.7 (47.2–75.0)

< 0.001

Dry mouth

33.3 (33.3–66.7)

33.3 (0.0-33.3)

0.014

Taste

66.7 (33.3–66.7)

33.3 (0.0-66.7)

0.013

Body image

66.7 (66.7–100.0)

66.7 (66.7–100.0)

0.200

Hair loss

0.0 (0.0–0.0)

0.0 (0.0–25.0)

0.787

DTR: double-tract reconstruction, EG: esophagogastrostomy, IQR: interquartile range

 

In addition, other postoperative symptoms were evaluated in the EORTC QLQ-STO22 questionnaire as a specific module for gastric cancer patients. Symptoms such as dysphagia (DYS) (P < 0.001), pain (PAIN) (P < 0.001), reflux (RFX) (P < 0.001), eating restrictions (EAT) (P = 0.001), anxiety (ANX) (P < 0.001), dry mouth (DM) (P = 0.014), and taste change (TA) (P = 0.013) occurred to a more serious degree in the EG group than in the DTR group, while aspects including body image (BI) and hair loss (HAIR) were the same in the two groups.

Discussion

The number of upper-third gastric cancer patients has been increasing in East Asia, including China, Japan and Korea(12, 2224). For patients meeting the criterion of radical proximal gastrectomy, PG is an organ-preserving surgery with several advantages over total gastrectomy(25, 26). However, the reconstruction method after PG has been controversial regarding prevention of reflux and improvement in QOL. Our study is the first prospective randomized controlled trial conducted to compare the incidence of reflux esophagitis, surgical safety, nutrition status and quality of life after EG or DTR in PG patients.

In the present study, the primary endpoint was the incidence of reflux esophagitis after surgery. The results demonstrated that the rate of reflux esophagitis was significantly lower in the DTR group than in the EG group (8.3% vs. 32.4%), and moreover, the severity of reflux esophagitis was much worse in the EG group, with 25% of the esophagitis patients classified as grade B, while none of the DTR group patients developed grade B reflux esophagitis according to the Los Angeles Classification of Gastroesophageal Reflux Disease. In other previous studies, it was demonstrated that the incidence of reflux esophagitis in the DTR group was significantly lower than that in the EG group (8-31.6% vs. 30.8–74%), which was consistent with our study(21, 27, 28). Moreover, in our study, it was proven in the multivariate analysis that the choice of reconstruction method was the only factor affecting the incidence of reflux esophagitis. The possible reason of DTR anti-reflux function might be that there is a 10–15 cm segment of jejunum interposed between the remnant stomach and the esophagojejunostomy and that, consequently, the gastric content rarely refluxes to the esophagus.

QOL is another important consideration when choosing a reconstruction method during organ-preserving gastrectomy, such as PG. It has been demonstrated that PG with DTR has QOL advantages over total gastrectomy in several previous studies(29, 30). However, few studies have focused on comparing the QOL of patients who have undergone EG or DTR after PG. In a retrospective study conducted by Eom et al., the QOL was balanced in the EG group and the DTR group, which was explained by the taking of proton-pump inhibitors to control reflux symptoms and the bias of retrospective research(31). In our study, patients who received DTR had superior results in several aspects of QOL, including global health status, emotional functioning and symptoms such as fatigue, nausea and vomiting, pain, insomnia, appetite loss, dysphagia, reflux, eating problems, anxiety, dry mouth and taste problems. Several studies have proven that gastroesophageal reflux disease impairs the health-related QOL of patients in all dimensions, both physically and psychologically(3234), which is consistent with our results that DTR group patients had more favorable QOL on both functional scales and symptom scales because of a lower incidence of reflux esophagitis than EG group patients.

The advantage of EG reconstruction is that the operation procedure is much simpler, while three anastomoses are required during DTR(35). As a result, the operation time was significantly longer in the DTR group than in the EG group in this study. Nevertheless, the perioperative safety remained the same between the two groups, which was in accordance with previous studies(21, 31). In addition, Miyauchi et al. found that more anastomotic stenosis occurs in EG patients, which might be a result of fundoplication during esophagogastric anastomosis(27). Another advantage of EG reconstruction is that the physiological passage of food through the remnant stomach to the duodenum was entirely preserved, which enhances the absorption of nutrients, especially iron and vitamin B12(16). It has been reported that the passage of food into the remnant stomach is the critical factor that determines the postoperative nutritional status after DTR (36). In our study, the side-to-side gastrojejunostomy was performed using a 60 mm linear stapler rather than a circular stapler to ensure a sufficient width of the anastomosis so that food could enter the remnant stomach smoothly, which was a possible reason why the postoperative nutritional status was balanced in the DTR group and the EG group.

Our investigation was the first prospective randomized controlled study to compare the incidence of reflux esophagitis, surgical safety, nutritional status and QOL between EG and DTR after PG. Thus, the study was sufficiently powered for the analyses and the results. However, there were also several disadvantages of this study. First, it was a single-center study and compared with multi-center study, there might be some selection bias. Second, only one year of follow-up was performed, and some differences might not appear in such a limited time. Our next research step is to continue the follow-up and update the data in future articles.

Conclusion

DTR is superior to EG after PG in terms of the incidence of reflux esophagitis after surgery and provides a more satisfactory nutritional recovery and QOL regarding both functional scales and symptom scales without increasing surgical complications. Thus, DTR could be a favorable reconstruction method after PG.

Abbreviations

GC: gastric cancer

EGJ: gastroesophageal junction

PG: proximal gastrectomy

QOL: quality of life

EG: esophagogastrostomy

DTR: double-tract reconstruction

JI: jejunal interposition

SD: standard deviation

GHS: global health status

EF: emotional functioning

PF: physical functioning

RF: role functioning

CF: cognitive functioning

SF: social functioning

FA: fatigue

NV: nausea and vomiting

PAIN: pain

SL: insomnia

AP: appetite loss

DY: dyspnea

CO: constipation

DI: diarrhea

FI: financial difficulties

DYS: dysphagia

RFX: reflux

EAT: eating restrictions

ANX: anxiety

DM: dry mouth

TA: taste change

BI: body image

HAIR: hair loss

Declarations

Ethics approval and consent to participate

The study conformed to the Declaration of Helsinki and was approved by the Ethics Committee of Peking University Cancer Hospital (No. 2018KT97). All patients volunteered to participate and signed informed consent forms before enrollment.

Consent for publication

Not applicable.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Competing interests

The authors declare that they have no competing interests.

Funding

This study was funded by the Research Incubation Project, Beijing Municipal Administration of Hospitals (PX2019039). The funding was used in data collection and management.

Authors' contributions

Xin Ji and Zhaode Bu proposed the study concept.

Xin Ji, Yan Yan, Yinan Zhang and Zhaode Bu designed the study.

Xin Ji, Ziyu Jia, Heli Yang, Biao Fan, Anqiang Wang contributed to the data acquisition and management.

Yinan Zhang, Xin Ji and Yan Yan made the statistical analysis and interpretation of the results.

Yinan Zhang, Xin Ji and Yan Yan prepared the manuscript and the editing and reviewing.

Zhaode Bu finally approved the manuscript.

Acknowledgements

We thank the patients, their families, and all the investigators, nurses, and study team at Peking University Cancer Hospital. We also thank Beijing Municipal Administration of Hospitals for the funding of this research.

References

  1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–49.
  2. Xie Y, Shi L, He X, Luo Y. Gastrointestinal cancers in China, the USA, and Europe. Gastroenterol Rep (Oxf). 2021;9(2):91–104.
  3. Yang L, Ying X, Liu S, Lyu G, Xu Z, Zhang X, et al. Gastric cancer: Epidemiology, risk factors and prevention strategies. Chin J Cancer Res. 2020;32(6):695–704.
  4. Zhang T, Chen H, Yin X, He Q, Man J, Yang X, et al. Changing trends of disease burden of gastric cancer in China from 1990 to 2019 and its predictions: Findings from Global Burden of Disease Study. Chin J Cancer Res. 2021;33(1):11–26.
  5. Buas MF, Vaughan TL. Epidemiology and risk factors for gastroesophageal junction tumors: understanding the rising incidence of this disease. Semin Radiat Oncol. 2013;23(1):3–9.
  6. Liu K, Yang K, Zhang W, Chen X, Chen X, Zhang B, et al. Changes of Esophagogastric Junctional Adenocarcinoma and Gastroesophageal Reflux Disease Among Surgical Patients During 1988–2012: A Single-institution, High-volume Experience in China. Ann Surg. 2016;263(1):88–95.
  7. Japanese Gastric Cancer A. Japanese gastric cancer treatment guidelines 2018 (5th edition). Gastric Cancer. 2021;24(1):1–21.
  8. National Health Commission Of The People's Republic Of C. Chinese guidelines for diagnosis and treatment of gastric cancer 2018 (English version). Chin J Cancer Res. 2019;31(5):707–37.
  9. Lee I, Oh Y, Park SH, Kwon Y, Park S. Postoperative nutritional outcomes and quality of life-related complications of proximal versus total gastrectomy for upper-third early gastric cancer: a meta-analysis. Sci Rep. 2020;10(1):21460.
  10. Park JY, Park KB, Kwon OK, Yu W. Comparison of laparoscopic proximal gastrectomy with double-tract reconstruction and laparoscopic total gastrectomy in terms of nutritional status or quality of life in early gastric cancer patients. Eur J Surg Oncol. 2018;44(12):1963–70.
  11. Chen J, Bu Z, Ji J. Surgical treatment of gastric cancer: Current status and future directions. Chin J Cancer Res. 2021;33(2):159–67.
  12. Yamashita H, Seto Y, Sano T, Makuuchi H, Ando N, Sasako M, et al. Results of a nation-wide retrospective study of lymphadenectomy for esophagogastric junction carcinoma. Gastric Cancer. 2017;20(Suppl 1):69–83.
  13. Yura M, Yoshikawa T, Otsuki S, Yamagata Y, Morita S, Katai H, et al. Oncological safety of proximal gastrectomy for T2/T3 proximal gastric cancer. Gastric Cancer. 2019;22(5):1029–35.
  14. Kurokawa Y, Takeuchi H, Doki Y, Mine S, Terashima M, Yasuda T, et al. Mapping of Lymph Node Metastasis From Esophagogastric Junction Tumors: A Prospective Nationwide Multicenter Study. Ann Surg. 2021;274(1):120–7.
  15. Sugiyama M, Oki E, Ando K, Nakashima Y, Saeki H, Maehara Y. Laparoscopic Proximal Gastrectomy Maintains Body Weight and Skeletal Muscle Better Than Total Gastrectomy. World J Surg. 2018;42(10):3270–6.
  16. Tanioka T, Waratchanont R, Fukuyo R, Saito T, Umebayashi Y, Kanemoto E, et al. Surgical and nutritional outcomes of laparoscopic proximal gastrectomy versus total gastrectomy: a meta-analysis. Surg Endosc. 2020;34(3):1061–9.
  17. Shaibu Z, Chen Z, Mzee SAS, Theophilus A, Danbala IA. Effects of reconstruction techniques after proximal gastrectomy: a systematic review and meta-analysis. World J Surg Oncol. 2020;18(1):171.
  18. Nunobe S, Ida S. Current status of proximal gastrectomy for gastric and esophagogastric junctional cancer: A review. Ann Gastroenterol Surg. 2020;4(5):498–504.
  19. Rosa F, Quero G, Fiorillo C, Bissolati M, Cipollari C, Rausei S, et al. Total vs proximal gastrectomy for adenocarcinoma of the upper third of the stomach: a propensity-score-matched analysis of a multicenter western experience (On behalf of the Italian Research Group for Gastric Cancer-GIRCG). Gastric Cancer. 2018;21(5):845–52.
  20. Tan L, Ran MN, Liu ZL, Tang LH, Ma Z, He Z, et al. Comparison of the prognosis of four different surgical strategies for proximal gastric cancer: a network meta-analysis. Langenbecks Arch Surg. 2022;407(1):63–74.
  21. Ji X, Jin C, Ji K, Zhang J, Wu X, Jia Z, et al. Double Tract Reconstruction Reduces Reflux Esophagitis and Improves Quality of Life after Radical Proximal Gastrectomy for Patients with Upper Gastric or Esophagogastric Adenocarcinoma. Cancer Res Treat. 2021;53(3):784–94.
  22. Gong Y, Wang P, Zhu Z, Zhang J, Huang J, Xu H. Clinicopathological Characteristics and Prognosis of Upper Gastric Cancer Patients in China: A 32-Year Single-Center Retrospective Clinical Study. Gastroenterol Res Pract. 2019;2019:9248394.
  23. Ahn SH, Lee JH, Park DJ, Kim HH. Comparative study of clinical outcomes between laparoscopy-assisted proximal gastrectomy (LAPG) and laparoscopy-assisted total gastrectomy (LATG) for proximal gastric cancer. Gastric Cancer. 2013;16(3):282–9.
  24. Sun D, Cao M, Li H, He S, Chen W. Cancer burden and trends in China: A review and comparison with Japan and South Korea. Chin J Cancer Res. 2020;32(2):129–39.
  25. Ma F, Guo D, Zhang B, Zhang Y, Peng L, Ma Q, et al. Short and long-term outcomes after proximal gastrectomy with double tract reconstruction for Siewert type III adenocarcinoma of the esophagogastric junction: a propensity score matching study from a 10-year experience in a high-volume hospital. J Gastrointest Oncol. 2020;11(6):1261–73.
  26. Peng R, Yue C, Wei W, Zhou B, Wen X, Gu RM, et al. Proximal gastrectomy may be a reasonable choice for patients with selected proximal advanced gastric cancer: A propensity score-matched analysis. Asian J Surg. 2021.
  27. Miyauchi W, Matsunaga T, Shishido Y, Miyatani K, Hanaki T, Kihara K, et al. Comparisons of Postoperative Complications and Nutritional Status After Proximal Laparoscopic Gastrectomy with Esophagogastrostomy and Double-Tract Reconstruction. Yonago Acta Med. 2020;63(4):335–42.
  28. Aburatani T, Kojima K, Otsuki S, Murase H, Okuno K, Gokita K, et al. Double-tract reconstruction after laparoscopic proximal gastrectomy using detachable ENDO-PSD. Surg Endosc. 2017;31(11):4848–56.
  29. Sato R, Kinoshita T, Akimoto E, Yoshida M, Nishiguchi Y, Harada J. Feasibility and quality of life assessment of laparoscopic proximal gastrectomy using double-tract reconstruction. Langenbecks Arch Surg. 2021;406(2):479–89.
  30. Lochman P, Koci J, Paral J. Quality of life after proximal gastrectomy a review. Rozhl Chir.97(8):368–72.
  31. Eom BW, Park JY, Park KB, Yoon HM, Kwon OK, Ryu KW, et al. Comparison of nutrition and quality of life of esophagogastrostomy and the double-tract reconstruction after laparoscopic proximal gastrectomy. Medicine (Baltimore). 2021;100(15):e25453.
  32. Chandran S, Raman R, Kishor M, Nandeesh HP. The effectiveness of mindfulness meditation in relief of symptoms of depression and quality of life in patients with gastroesophageal reflux disease. Indian J Gastroenterol. 2019;38(1):29–38.
  33. Maret-Ouda J, Markar SR, Lagergren J. Gastroesophageal Reflux Disease: A Review. JAMA. 2020;324(24):2536–47.
  34. Lee SW, Chang CS. Impact of Overlapping Functional Gastrointestinal Disorders on the Quality of Life in Patients With Gastroesophageal Reflux Disease. J Neurogastroenterol Motil. 2021;27(2):176–84.
  35. Tominaga S, Ojima T, Nakamura M, Katsuda M, Hayata K, Kitadani J, et al. Esophagogastrostomy With Fundoplication Versus Double-tract Reconstruction After Laparoscopic Proximal Gastrectomy for Gastric Cancer. Surg Laparosc Endosc Percutan Tech. 2021;31(5):594–8.
  36. Yamashita K, Iwatsuki M, Koga Y, Toihata T, Kiyozumi Y, Kuroda D, et al. Preservation of physiological passage through the remnant stomach prevents postoperative malnutrition after proximal gastrectomy with double tract reconstruction. Surg Today. 2019;49(9):748–54.